Laventair Ellipta is a medicine used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults. COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing. Laventair Ellipta is used for maintenance (regular) treatment. Laventair Ellipta contains the active substances umeclidinium bromide and vilanterol.
Therapeutic Indication
### Therapeutic indication Laventair Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Therapeutic Area (MeSH)
ATC Code
R03AL03
ATC Item
vilanterol and umeclidinium bromide
Pharmacotherapeutic Group
Drugs for obstructive airway diseases
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| umeclidinium bromide | N/A | GSK-573719 |
| vilanterol | N/A | 维兰特罗 |
EMA Name
Laventair Ellipta (previously Laventair)
Medicine Name
Laventair Ellipta (previously Laventair)
Aliases
N/ANo risk management plan link.
